The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental new drug application (sNDA) for Camzyos…
Read More
Apnimed Secures Up to $150 Million in Credit Facility to Fuel Potential US Launch of Obstructive Sleep Apnea Therapy AD109
Boston, MA – – Apnimed, a clinical-stage biopharmaceutical company focused on developing novel therapies for sleep-related breathing disorders, has announced…
Read MoreYOU MAY HAVE MISSED
